Evidence map›Paper›PMID 16930454›Full record

ArticleMolecular neurodegeneration2006

Tumor suppressor PTEN affects tau phosphorylation: deficiency in the phosphatase activity of PTEN increases aggregation of an FTDP-17 mutant Tau.

Xue Zhang, Yun-wu Zhang, Shijie Liu, Ayelen Bulloj, Gary G Tong, Zhuohua Zhang, Francesca-Fang Liao, Huaxi Xu

Open access · goldAbstract read
In one paragraph

Article in Molecular neurodegeneration, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Targeting the HDAC2/HNF-4A/miR-101b/AMPK Pathway Rescues Tauopathy and Dendritic Abnormalities in Alzheimer's Disease.Molecular therapy : the journal of the American Society of Gene Therapy · 2017
    Article
  6. Article
  7. Article
  8. A network view on Parkinson's disease.Computational and structural biotechnology journal · 2013
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Xue ZhangCenter for Neuroscience and Aging, Burnham Institute for Medical Research, 10901 N, Torrey Pines Road, La Jolla, CA 92037, USA. zhangxue@burnham.org
Yun-wu Zhang
Shijie Liu
Ayelen Bulloj
Gary G Tong
Zhuohua Zhang
Francesca-Fang Liao
Huaxi Xu
Sanford Burnham Prebys Medical Discovery Institute · US

Funding

VIRUS-INDUCED BRAIN PATHOLOGYP50AG005131 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GALASKO, DOUGLAS R · 1985 to 2018
$55.4M
Regulation of Protein Trafficking in NeurodegenerationR01NS046673 · NINDS · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI XU, HUAXI · 2003 to 2018
$5.8M
NEUROBIOLOGICAL ASPECTS OF AGINGK12AG000975 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TUSZYNSKI, MARK H. · 2000 to 2009
$4.3M
New Roles for sAPP in Neuroprotection and NeurogenesisR01NS054880 · NINDS · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI LIAO, FRANCESCA-FANG · 2006 to 2010
$1.9M
Pathogensis of Disease-Associated Connexin-31 MutationsR01DC006497 · NIDCD · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ZHANG, ZHUOHUA · 2004 to 2008
$1.7M
Roles of APP in tauopathyF32AG024895 · NIA · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ZHANG, YUNWU · 2005 to 2007
$156k
NIA NIH HHS F32 AG024895NIA NIH HHS K12 AG000975NIA NIH HHS P50 AG005131NIDCD NIH HHS R01 DC006497NINDS NIH HHS R01 NS046673NINDS NIH HHS R01 NS054880
6 · The paper itself

Abstract

backgroundAberrant hyperphosphorylation of tau protein has been implicated in a variety of neurodegenerative disorders. Although a number of protein kinases have been shown to phosphorylate tau in vitro and in vivo, the molecular mechanisms by which tau phosphorylation is regulated pathophysiologically are largely unknown. Recently, a growing body of evidence suggests a link between tau phosphorylation and PI3K signaling. In this study, phosphorylation, aggregation and binding to the microtubule of a mutant frontal temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) tau in the presence of tumor suppressor PTEN, a major regulatory component in PI3K signaling, were investigated.

resultsPhosphorylation of the human mutant FTDP-17 tau, T40RW, was evaluated using different phospho-tau specific antibodies in the presence of human wild-type or phosphatase activity null mutant PTEN. Among the evaluated phosphorylation sites, the levels of Ser214 and Thr212 phospho-tau proteins were significantly decreased in the presence of wild-type PTEN, and significantly increased when the phosphatase activity null mutant PTEN was ectopically expressed. Fractionation of the mutant tau transfected cells revealed a significantly increased level of soluble tau in cytosol when wild-type PTEN was expressed, and an elevated level of SDS-soluble tau aggregates in the presence of the mutant PTEN. In addition, the filter/trap assays detected more SDS-insoluble mutant tau aggregates in the cells overexpressing the mutant PTEN compared to those in the cells overexpressing wild-type PTEN and control DNA. This notion was confirmed by the immunocytochemical experiment which demonstrated that the overexpression of the phosphatase activity null mutant PTEN caused the mutant tau to form aggregates in the COS-7 cells.

conclusionTumor suppressor PTEN can alleviate the phosphorylation of the mutant FTDP-17 tau at specific sites, and the phosphatase activity null PTEN increases the mutant tau phosphorylation at these sites. The changes of the tau phosphorylation status by ectopic expression of PTEN correlate to the alteration of the mutant tau's cellular distribution. In addition, the overexpression of the mutant PTEN can increase the level of the mutant tau aggregates and lead to the formation of visible aggregates in the cells.

Identifiers

PMID16930454
PMCPMC1559623
OpenAlexW2161909550

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.